In 2017 Mitsubishi Tanabe Pharma established the Future Design Department. The Future Design Department is advancing a transformation to a data-driven company with a view to the use of Big Data, AI, IoT, Digital Medicine and other digital technologies with the objective of fostering "disruptive innovation" in the pharmaceutical business. We are working to create new methods that transcend the pharmaceutical industry's conventional pharmaceutical categories. Mitsubishi Tanabe Pharma is promoting open innovation with some universities and companies of different industries about issues with impact within the drug discovery value chain.
For example, Mitsubishi Tanabe Pharma and Hitachi have initiated collaborative creation for improving the efficiency of clinical trials using Hitachi's advanced digital technology such as AI.
In another example, in 2018, we will start an accelerator program. With the key words of "creating the future of healthcare" we will build a business model that transcends the conventional pharmaceutical business framework and strive to contribute to the happiness and health of patients and those around them.
In order to expand our business "around the pill" and "beyond the pill", we are working on the challenge of creating new value in the fields of medicine and healthcare through cross-industry collaboration with cutting edge technologies and different industries. In this presentation, we would like to introduce the above contents along the case of Future Design Department in Mitsubishi Tanabe Pharma.